DIAGNOSTIC SIGNIFICANCE OF BIOCHEMICAL MARKERS IN VETERINARY CLINICAL BIOCHEMISTRY

Abstract

The chapter "Diagnostic Significance of Biochemical Markers in Veterinary Clinical Biochemistry" explores the pivotal role of biochemical markers in veterinary medicine. Biochemical markers are crucial for diagnosing various animal diseases, predicting prognosis, and monitoring treatment responses. This chapter delves into the intricate relationships between biochemistry and veterinary practice, emphasizing their significance in identifying factors contributing to intoxication and formulating effective treatment protocols. The chapter discusses a wide array of biochemical markers, including those related to liver and kidney function, electrolytes, cardiac health, metabolic indicators, endocrine markers, inflammatory and immune markers, mineral and vitamin markers, and diagnostic profiles. It also addresses the challenges and limitations associated with using biochemical markers, highlighting the importance of considering factors such as age, breed, and sex. Case studies and clinical applications provide real-world examples of the diagnostic process. The chapter concludes by examining future trends in veterinary diagnostic biochemistry, including advances in diagnostic technology and the integration of biochemistry with other diagnostic methods.

Keywords: Veterinary medicine, biochemical markers, diagnostic significance, liver function, kidney function, cardiac markers, metabolic markers.

Authors

Bhagraj Godara
Ph. D Scholar
Animal Biochemistry
ICAR-National Dairy Research Institute
Karnal,Haryana, India.
drbhagrajgodara@gmail.com

Rashmeet Kaur
Ph. D Scholar
Animal Biotechnology ICAR-National
Dairy Research Institute
Karnal, Haryana, India.

I. INTRODUCTION

In the rapidly developing field of veterinary medicine, the application of biochemical markers as a diagnostic and therapeutic tool for a wide variety of animal diseases has emerged as an essential approach. These biochemically produced indicators give essential insights into an animal's health status, aiding in the early detection of sickness, in the prediction of prognosis, and in the monitoring of treatment.

Consider, for instance, a dairy cow displaying subtle signs of illness. Through the analysis of specific biochemical markers in its blood or bodily fluids, veterinarians can swiftly identify the underlying issue, whether it be an infectious disease, metabolic disorder, or nutritional deficiency. This timely diagnosis can mean the difference between life and death for the animal and has profound implications for the productivity of a dairy herd.

The utilization of the biochemical method in veterinary medicine is of utmost importance in the identification of the fundamental factors contributing to intoxication and the formulation of efficacious treatment protocols. Biomarkers are measurable signs that can be used to diagnose a disease. The phrase "biomarker" refers to cellular, biochemical, or molecular modifications in cells, tissues, or fluids. Quantifying and assessing these alterations can reveal biological activities, disease processes, and treatment outcomes.

The concepts of animal health and welfare are considered essential principles from both a societal and scientific perspective. It is crucial to separate biomarkers linked with diseases from those associated with drugs. Disease biomarkers, including risk indicators or predictive biomarkers, and prognostic biomarkers, can help patients predict the course of a disease regardless of treatment. Predictive biomarkers determine a therapy's response, whereas prognostic signs reveal a disease's fate independent of treatment. On the other hand, medication-related biomarkers let patients assess their drug metabolism and therapeutic effectiveness.

This chapter elucidates the vital relevance of biochemical markers by delving into the intricate relationships that exist between biochemistry and veterinarians. We will explore the diverse categories of biochemical markers and their specific applications in veterinary medicine, shedding light on how these markers are not only diagnostic tools but also essential components in ensuring the health and welfare of animals. Furthermore, we will emphasize the dynamic and evolving nature of this field, where new biomarkers and diagnostic techniques continually expand our capabilities in diagnosing and managing veterinary diseases. Whether you are a veterinarian, researcher, clinician, or simply intrigued by the fascinating intersection of biochemistry and animal health, this chapter offers valuable insights into a subject of paramount importance in modern veterinary medicine.

II. BLOOD BIOCHEMICAL MARKERS

In veterinary medicine, various blood biochemical markers play a crucial role in assessing the health status of different animal species. One of the key organs that these markers help evaluate is the liver, a multifunctional powerhouse in the body responsible for tasks ranging from glucose to lipid and protein metabolism. Liver function is pivotal for an animal's overall well-being, and its failure can lead to a wide array of clinical and metabolic disorders.

The liver's unique characteristic is that it receives a substantial portion (about 75%) of its blood supply through the portal venous system. This system drains several abdominal organs, including the gastrointestinal (GI) tract, spleen, and pancreas. Consequently, disorders affecting these organs can have secondary consequences on the liver. Moreover, the liver plays a pivotal role in metabolizing and eliminating exogenous substances, such as medications and toxins, which can potentially induce liver damage as a secondary effect.

Elevations in liver enzyme activity are frequently observed in small animal practice, serving as indicators of various liver diseases, including hepatocellular injury, cholestasis, or a combination of both. However, it's important to note that liver enzymes, particularly alkaline phosphatase (ALP), lack specificity in diagnosing primary liver disease. To establish their clinical relevance, veterinarians must consider a comprehensive range of factors, including patient history, clinical symptoms, physical examination findings, diagnostic imaging results, and other liver function tests.

Additional alterations in laboratory parameters, such as hypocholesterolemia or hypoalbuminemia, may further indicate hepatic dysfunction. To enhance the precision of liver function assessment, parameters like serum bile acids (SBA) or ammonia concentrations can be employed. Nevertheless, it's imperative to recognize that individuals with normal liver function test results can still be afflicted by liver disease. Therefore, while laboratory tests are pivotal in identifying liver disease in dogs and cats, a definitive diagnosis typically requires the integration of diagnostic imaging and the evaluation of liver tissue through cytological or histological methods.

Serum liver enzymes offer a high degree of sensitivity, but their specificity as indicators for primary hepatobiliary disease is not absolute. These enzymes include alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which indicate hepatocellular injury, and alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT), which indicate cholestasis. Each of these enzymes can provide valuable insights into the presence of liver disease and guide the differential diagnosis process. In veterinary medicine, dogs and cats are commonly domesticated animals and are often kept as pets, making the understanding of these biochemical markers essential for their health assessment.

Blood urea nitrogen (BUN) and creatinine are two vital markers used to assess renal function in animals. BUN is a byproduct resulting from protein breakdown, while creatinine is generated as part of normal muscle metabolism. Both substances are typically removed from the circulatory system through renal filtration, making them reliable markers for evaluating kidney function.

Elevations in BUN and creatinine levels can indicate renal dysfunction, dehydration, or other conditions that impede renal blood flow. The extent of renal dysfunction can be assessed by evaluating the magnitude of the increase in BUN and creatinine levels. However, it's important to note that these markers exhibit significant elevations only when approximately 75% of renal function has already been compromised.

Some laboratories also offer an additional blood test, symmetrical dimethylarginine (SDMA), for assessing kidney function. SDMA can detect renal disease earlier than BUN and creatinine, making it a valuable tool for the early detection of kidney illness. In summary, the assessment of renal function through biochemical markers is vital for diagnosing and managing kidney-related conditions in veterinary medicine.

III.CARDIAC MARKERS

Cardiac troponins are vital quantitative indicators of myocardial injury, offering consistent measurability in both dogs and cats. These markers provide valuable prognostic insights, irrespective of clinical context (acute or chronic), the suspected nature of myocardial injury (reversible or irreversible), or underlying disease (cardiac or noncardiac). Troponins, from a clinical perspective, hold a notable advantage due to their remarkable negative predictive value, applicable to both cardiac and noncardiac conditions. Lower troponin levels typically signify a higher likelihood of survival, while elevated levels suggest a greater risk of mortality.

In the field of veterinary medicine, cardiac troponin I (cTnI) has been the marker of choice. Heart troponin T is less sensitive and is produced only in cases of severe heart damage. Given the infrequent occurrence of acute myocardial infarction (AMI) in dogs and cats and the common association of primary cardiac diseases with mild myocardial damage, cTnI emerged as the preferred option in initial troponin investigations in animals. Currently, more advanced cTnT assays are accessible, making this marker increasingly available for veterinary research. Both cardiac troponin I and cTnT exhibit minor variations in predictive capabilities, and either marker is deemed satisfactory for clinical assessment. Considering the significant prognostic implications even with minor myocardial damage, cTnI remains the preferred biomarker for assessing cardiac injury in canines and felines.

In veterinary studies, correlations have been observed between cardiac troponin levels and short-term mortality in dogs affected by gastric dilatation volvulus (GDV), parvoviral enteritis, babesiosis, systemic inflammatory response syndrome (SIRS), and systemic inflammation in dogs without underlying structural cardiac conditions. However, further research is needed to assess the efficacy of repeated troponin readings in monitoring individual patients.

The predictive value of cardiac troponins for long-term outcomes remains a subject of ongoing debate. Some investigations have yielded inconclusive results regarding a correlation, while others suggest that myocardial damage may potentially serve as a prognostic indicator for adverse long-term outcomes, contributing to eventual clinical deterioration. Previous studies have shown a correlation between admission (cTnT) and peak (cTnI) troponin concentrations in dogs and the 1-year case fatality rate. However, it's essential to note that this link is considerably weaker than its association with short-term case fatality. cTnI demonstrates superior predictive ability in the short term, while cTnT exhibits greater confidence in predicting long-term outcomes. Therefore, troponins may serve as complementary prognostic indicators. Close monitoring after hospital release may be necessary for severely ill individuals displaying signs of myocardial damage due to the potential correlation between long-term outcomes and cardiac troponin levels. Consequently, cardiac troponins may serve as valuable tools for identifying patients at long-term risk in the intensive care unit, encompassing both animal and human subjects.

IV. CREATINE KINASE (CK) AS A MUSCLE INJURY MARKER

Creatine kinase (CK) is an enzyme that facilitates the bidirectional transfer of phosphate groups, essential for energy storage and utilization in skeletal muscle. Additionally, CK plays a secondary role in translocating energy from mitochondria to the cytoplasm in various tissues. CK is ubiquitously present in many tissues, with prominent activity in organs with elevated energy demands, such as skeletal muscle, cardiac muscle, and brain tissue. CK primarily resides in the cytosol, and its release into the bloodstream due to trauma or illness results in elevated CK activity, causing hyperCKemia. Consequently, CK serves as a distinctive biomarker for muscle fiber injury. The evaluation of total creatine kinase (CK) activity in blood encompasses the combined assessment of CK-MM, CK-MB, and CK-BB isoenzyme activities, corresponding to skeletal muscle, cardiac muscle, and brain tissue, respectively. In dogs and cats, CK-MM is the prevailing isoenzyme.

Elevated serum CK enzyme activity in canines is frequently associated with several disease classifications, including necrotizing myopathies, widespread or localized inflammatory myopathies, and congenital or inherited muscle diseases. The degree and persistence of elevated blood CK enzyme levels often serve as indicators of the seriousness and ongoing nature of muscle damage, aiding in prioritizing plausible differential diagnoses. Markedly elevated serum CK enzyme activity, particularly exceeding 20,000 IU/L, typically indicates necrotizing myopathies or inherited muscular dystrophic diseases. Necrotizing myopathies are typically characterized by at least one clinical manifestation, such as myalgia, fever, stilted gait, generalized weakness, decreased spinal reflexes, exercise intolerance, anorexia, lethargy, pigmenturia, or dysphagia. These symptoms may result from various factors, including drugs, toxins, snake bites, insect stings, ischemic myopathy, electrolyte disorders (e.g., hypokalemia), endocrinopathies, excessive exertion, hyperthermia, infectious diseases, or may have an unknown cause (idiopathic). Hereditary muscular dystrophies may exhibit modest clinical manifestations in early stages but often have a progressive nature. Typically, generalized and localized inflammatory myopathies result in moderate (i.e., 2,000–20,000 IU/L) and mild (i.e., 0–2,000 IU/L) elevations in blood creatine kinase (CK) enzyme activity, respectively. Generalized inflammatory myopathies have clinical manifestations similar to necrotizing myopathies and can result from various causes, including infectious agents, immune-mediated mechanisms, or paraneoplastic processes.

B-type natriuretic peptide (BNP) is a hormone synthesized and released by cardiomyocytes, the cells of the cardiac muscle, in response to excessive stretching. Its role in maintaining intravascular volume and systemic pressure balance is crucial, counteracting the effects of the renin-angiotensin-aldosterone system (RAAS), which is often heightened in cardiac disease. BNP facilitates salt and water excretion through renal mechanisms and induces vasodilation, collectively reducing cardiac strain and workload. Elevated stretching of cardiomyocytes and increased release of BNP are commonly associated with various cardiac disorders. The severity of heart disease correlates positively with the extent of elevation in circulating BNP levels.

Cardiomyocytes release BNP as a precursor prohormone, which undergoes cleavage, resulting in two distinct fragments: a bioactive C-terminal fragment known as C-BNP and an inert fragment referred to as NT-proBNP. C-BNP has a brief half-life of approximately 90 seconds, limiting its accuracy in measurement. In contrast, NT-proBNP, with a longer half-life of around 120 minutes and improved stability during sample processing, is highly suitable for diagnostic purposes.

Measurement of NT-proBNP levels is conducted in serum, available through external laboratories or in-clinic tests, including a recently introduced rapid quantification method. Incorporating quantitative NT-proBNP test results into clinical evaluations can aid in identifying dogs with advanced cardiac pathology, guiding the need for additional diagnostic procedures. Additionally, this approach can monitor canines with pre-existing cardiac conditions. Diagnosing dogs with respiratory symptoms can be challenging. NT-proBNP measurement provides valuable assistance in the diagnostic process. Respiratory illness often correlates with normal or low NT-proBNP concentrations, while increased levels (>2,500 pmol/L) indicate cardiac disease.

Furthermore, findings from NT-proBNP testing, particularly levels exceeding 1500 pmol/L in dogs with documented mitral valve disease (MMVD) history and observable thoracic radiograph alterations, can identify advancing cardiac pathology and anticipate a higher likelihood of congestive heart failure (CHF) occurrence within 3 to 6 months.

Integrating NT-proBNP evaluation with additional diagnostic measures enhances screening effectiveness. Recent studies suggest that combining NT-proBNP data with commonly used clinical values can create predictive models to identify dogs at an increased risk of being diagnosed with stage B2 MMVD. This integration improves the accuracy of cardiac assessments and aids in early intervention, contributing to better patient care in veterinary cardiology.

V. METABOLIC MARKERS

Hyperlipidemia is widely recognized as a prevalent characteristic among dogs that are fat, with estimates suggesting that around 24% to 30% of dogs fall into the overweight or obese category. Hyperlipidemic circumstances have the potential to exacerbate the development of metabolic syndrome in canines. The degree of hyperlipidemia in dogs may be influenced by physiological characteristics, including age, body weight, and sex. Previous studies have documented the impact of the ageing process on plasma levels of total cholesterol and triglycerides in hyperlipidemic canines. The occurrence of hyperlipidemia in elderly canines appears to be influenced by factors such as nutritional status, inflammation, and oxidative stress, which parallels the situation observed in elderly people. Plasma malondialdehyde (MDA) concentrations are commonly recognized as an indicator of lipid peroxide stress. Previous studies have demonstrated a positive association between plasma lipid peroxide levels and the elevated incidence of diabetes in human subjects. Superoxide dismutase and glutathione peroxidase are enzymes that have been shown to have increased levels in response to elevated oxidative stress. Alpha 1-acid glycoprotein is a protein synthesized in the liver as a reaction to inflammation, functioning as an acute-phase reactant. The release of non-esterified fatty acids (NEFA) from adipocytes in excessive amounts leads to the development of lipotoxicity. Plasma insulin and adiponectin are endocrine factors that serve as indicators of the level of insulin resistance. The complexity of lipid metabolic problem in dogs is further compounded by the influence of nutritional conditions, inflammation, and oxidative stress, all of which are subject to the effects of aging.

Lactate, a byproduct of anaerobic metabolism of glucose, is recognized as a diagnostic and prognostic biomarker for shock in the field of veterinary medicine. It can also serve as an indicator for identifying hypoperfusion, but with some limits. The research findings indicate that elevated levels of blood lactate in equines are associated with a lower likelihood of survival, suggesting that it serves as an unfavorable prognostic marker. Research on lactate in small animal medicine has been focused on canines. The assessment of lactate levels in canines that are seriously ill or injured may hold significance in forecasting the gravity of the condition and its eventual result. One study revealed notable distinctions between dogs afflicted with severe babesiosis and hyperlactatemia, and diseased dogs exhibiting normal lactate levels. These differences were observed in various aspects, including the occurrence of clinical collapse, alanine transaminase activity, biluribin levels, urea levels, creatinine levels, bicarbonate levels, pCO_2 levels, and the degree of parasitaemia. Hence, the measurement of lactate concentration can serve as a valuable marker for assessing the severity of a disease and its association with clinical manifestations and changes in other hematological parameters.

The first proposition of amylase as a biomarker for acute pancreatitis (AP) was based on experimental experiments conducted in dogs. However, subsequent investigations revealed that its performance was not perfect, leading researchers to explore alternative biomarkers. The lack of precise specificity is likely attributed to the fact that amylase originates from different tissues. It is evident that canines that have had complete pancreatectomy continue to exhibit significant levels of serum amylase activity. Although the studies found that blood amylase activity had only modest diagnostic performance, tests assessing pancreatic lipase showed better results in the same research designs when using the suggested diagnostic cut-offs. Furthermore, previous research employing clinical symptoms and histology as reference standards has demonstrated significantly lower sensitivities ranging from 7% to 40.9%. There is evidence indicating that dogs with impaired renal function have elevated levels of amylase activity, hence potentially complicating the interpretation of this enzyme's activity. Consequently, the inclusion of serum amylase activity in the usual diagnostic protocol for acute pancreatitis (AP) in canines is no longer deemed necessary. Nevertheless, in cases when there is a significant elevation in serum amylase activity (exceeding 3-5 times the upper reference interval) in a canine patient displaying clinical symptoms indicative of a particular condition, it is important to consider pancreatitis as a potential differential diagnosis.

Pancreatic lipase is generated from pancreatic acinar cells and, under typical physiological circumstances, only a little amount is introduced into the systemic circulation. Pancreatic lipase is abundantly released into the systemic circulation during pancreatic inflammation, making it a viable diagnostic for acute pancreatitis. In terms of methodology, lipase tests can be categorized as either catalytic or immunologic in nature. Catalytic assays serve as a means to assess the enzymatic activity of a given sample. This is achieved by quantifying the usage of substrates or the build-up of products. In the case of lipase, these assays often involve the hydrolysis of various substrates by numerous possible lipases. Colorimetric reactions serve as the detection technique, with the outcomes being reported in terms of enzyme activity. The specificity of an assay can be affected by several factors, including the choice of substrate, as well as the presence of cofactors like bile acids or colipase, the pH of the assay, and the wavelength employed for measuring light absorption. In contrast, immunological tests employ antibodies as a means to quantify enzyme concentration. Selective tests utilize antibodies that exhibit specificity towards canine pancreatic lipase. The efficacy of these tests is contingent upon the adherence to particular methodological requirements. One possible method for assessing the specificity of an assay involves quantifying the lipase concentration in canines that are anticipated to have significantly reduced levels of pancreatic lipase. The presence of significant levels of measurable enzyme in these canines would indicate the identification of lipase originating from non-pancreatic origins.

VI. ENDOCRINE MARKERS

In addition to assessing serum levels of total thyroxine (TT4), total tri-iodothyronine (TT3), and free thyroxine (FT4), the diagnostic thyroid profile also includes the evaluation of T4 antibodies (T4AA), T3 antibodies (T3AA), canine thyrotropin (cTSH; thyroid stimulating hormone), and thyroglobulin antibodies (TgAA). The cTSH test offers valuable insights when attempting to identify hypothyroidism. There are several non-thyroidal causes that can lead to reductions in TT4, TT3, and FT4 levels, resulting in a hypothyroid state in dogs with normal thyroid function. This poses a challenge in distinguishing between animals who are ill but euthyroid and those that have hypothyroidism. In cases of primary hypothyroidism, a condition characterized by low thyroid hormone levels, it is shown that a majority of animals (about 75%) have elevated levels of cTSH.

The antibodies T3AA, T4AA, and TgAA serve as indicators of lymphocytic inflammation occurring inside the thyroid gland. T3AA and T4AA are subsets of TgAA that are observed in a subset of animals that test positive for TgAA. The T3 autoantibodies (T3AA) and T4 autoantibodies (T4AA) exhibit cross-reactivity with T3 or T4 in immunoassays, leading to erroneous outcomes in some thyroid hormone tests. Hence, it is imperative to ascertain their presence prior to interpreting the outcomes of thyroid hormone assessments.

Antibodies that exhibit cross-reactivity with thyroxine (T4) and/or triiodothyronine (T3) serve as indicators for the presence of lymphocytic thyroiditis in canines. The antibodies under consideration are produced in response to epitopes found on the thyroglobulin molecule that contain T4 and T3. In other words, these antibodies are specific subsets of thyroglobulin autoantibodies (TgAA). Positive readings are indicative of disease in the thyroid gland and provide information on the veracity of the results pertaining to thyroid hormone levels.

The quantification of cortisol levels in hair is a non-intrusive methodology employed for various applications, encompassing both human and animal subjects. Numerous research have thus far documented the assessment of cortisol hormone levels in the hair of many wildlife species, including squirrels, chimps, and bears.

Hair cortisol analysis has the potential to serve as a valuable evaluation tool for quantifying chronic stress in dogs. Consequently, it might also be considered as a useful supplementary measure for identifying specific hormonal disorders and evaluating the overall well-being of canines. The primary benefits of employing this approach are the ease and simplicity of hair sampling, which is a non-invasive process that does not necessitate prolonged animal confinement. Additionally, hair samples may be maintained for extended durations. Therefore, the utilization of HCC determination is a suitable approach for evaluating the extended excessive production of glucocorticoids in canines. Hair cortisol analysis has the potential to serve as a valuable tool for evaluating the well-being of working dogs, whose optimal physical and mental condition is vital for their performance of assigned duties. Additionally, this technique could be applied to shelter dogs, kennel dogs, and laboratory dogs to gain insights into their past experiences and address any behavioral issues they may exhibit.

VII. INFLAMMATORY AND IMMUNE MARKERS

In the field of veterinary medicine, the C-reactive protein, often known as CRP, is employed rather frequently. In instances when the disease is severe and is accompanied by systemic inflammatory response syndrome (SIRS), its levels in dogs have a tendency to considerably increase. This is the case regardless of whether the inflammation is primary or is accompanied by other conditions. According to the findings of a number of studies, the predictive value of C-reactive protein (CRP) does not lay in the absolute amount of the protein but rather in the pace at which it decreases with time. This is especially important to keep in mind while dealing with life-threatening medical conditions like sepsis. It was observed that dogs with acute abdomen that demonstrated such a drop ultimately succumbed to their disease. Despite this, a decline that is excessively quick might perhaps serve as a signal of a poor prognosis. However, as opposed to relying just on a single test performed upon admission, which is typically seen as an additional and less significant diagnostic signal, it is possible that the study of CRP levels during multiple measurements up to the patient's recovery would reveal more pertinent insights. This is due to the fact that CRP values tend to remain rather stable over time. In addition, monitoring the concentration of C-reactive protein (CRP) over time over the period of follow-up may make it easier to distinguish between dogs that respond to therapy and those who do not, but with the possibility of some outliers.

C-reactive protein (CRP) should not be evaluated in a vacuum and should not be relied upon as the sole diagnostic test. This is an additional point that must be emphasized. Instead, you should utilize it in combination with other diagnostic procedures in order to get the most accurate results. It is essential to view CRP not as a cost-effective replacement for complete diagnostic examination, but rather as an additional tool to be used in conjunction with it. It is recommended that the process of diagnosing inflammatory illnesses be made easier by utilizing mobile applications (APPs) with more thorough patient profiles and carrying out a number of different tests while the patient is being treated for their condition.
In addition to this, the half-life of canine CRP is relatively short, and its rise happens quite quickly after the beginning of an inflammatory stimulus that upsets homeostasis. This is in line with what is currently known in the scientific community. In most cases, the presence of high levels of C-reactive protein (CRP) does not give information that is sufficient to define the underlying cause or to precisely identify bacterial inflammation.

Applications, also known as APPs, have recently emerged as potentially useful diagnostic tools for the early identification of diseases in a number of subspecialties within the field of veterinary medicine. These APPs make it possible to continue monitoring the progression of the disease and assessing how well the medication is working. However, it is crucial to be aware that mobile apps (APPs) should not be relied upon solely as diagnostic indicators of illness. Instead, evaluation of these factors needs to take place in tandem with clinical workup. The use of SAA in the diagnosis of complicated illnesses, such as subclinical endometritis, has been demonstrated to be useful in the setting of animal reproductive. This biomarker shows potential in that it will be able to provide insights on the progression of the disease that was just discussed.

In clinical practice, the utilization of SAA evaluation on a routine basis is subject to some constraints due to the existence of practical factors. On the one hand, despite the broad availability of portable equipment, the process of assessing SAA continues to be time-consuming and relatively expensive. As a result, the widespread application of APP evaluation in regular clinical settings is limited as a result of these factors. In addition, the lack of defined reference ranges for domestic species continues to be a barrier to the clinical use of acute phase proteins (APPs). Despite this, it is of the utmost importance to encourage the development and refining of equipment that are both efficient and cost-effective for the measurement of serum amyloid A (SAA) levels. This is because acute-phase protein-based diagnostic approaches have a wide variety of potential applications in the field of veterinary reproduction, which is why this is the case.

It has been established that the use of SAA can provide diagnostic and prognostic aid in the monitoring of the progression of sepsis and post-operative inflammation in cases of subclinical endometritis, endometrial hyperplasia, and pyometra seen in dogs and felines.
Endometritis is the major cause of subfertility and infertility in cows, and it can be caused by a number of different factors. It is possible that the existence of a reliable indication might be of significant use to doctors in the process of identifying and continuing to examine these illnesses.

In small ruminants, the relevance of serum amyloid A (SAA) is of great importance in minimizing the economic losses associated with reproductive disorders, particularly in the context of rural family settings.

Within the realm of equine medicine, research into the serum and endometrial production of acute phase proteins (APPs) and other cytokines implicated in uterine defense mechanisms has the potential to make a contribution to the development of innovative therapeutic options for endometritis. In addition, it is possible that this research may make it easier to identify other diagnostic mediators or indicators that are associated with infertility in horses.

In conclusion, the substantial increase in SAA levels that was seen at the beginning of the acute phase response (APR) supports SAA as a highly sensitive and early biomarker that may identify inflammation in domestic animals. In the field of animal reproduction, the usefulness of SAA as a diagnostic tool is enhanced by the aforementioned characteristics. This is because the prompt detection and subsequent therapy of reproductive diseases are essential for the maintenance of fertility.

VIII. MINERALS AND VITAMINS MARKERS

The existence of indicators that are related with minerals and vitamins has a substantial impact on both the analysis of an individual's nutritional status and the evaluation of their general health.These indicators offer extremely helpful information on probable shortages or excesses of particular minerals or vitamins in the body.Monitoring these indicators can help in the diagnosis of nutritional deficiencies, provide direction for dietary adjustments, and assist to the improvement of an individual's general health.

Aspects of the Environment That Can Affect the Mineral Makeup: Calcium (Ca) is an essential component that plays a pivotal role in providing enough levels of calcium in the bloodstream. This plays a direct role in the maintenance of good bone health, as well as the facilitation of normal muscle and nerve function. There is some evidence that suggests that osteoporosis and other bone diseases may be linked to low levels of certain chemicals. Iron (Fe) is an essential component of the process that allows oxygen to go through the circulation more easily. Anemia, which is caused by low levels of iron, can cause symptoms such as fatigue and a general feeling of weakness. Electrolytes, such as sodium (Na) and potassium (K), have a significant impact on the facilitation of neuronal activity as well as the maintenance of the correct balance of fluids throughout the body. Both blood pressure and overall hydration can be affected when there is an imbalance. Magnesium, abbreviated as Mg, is an essential element that plays a vital role in a wide variety of metabolic activities. These actions are essential to ensuring that the muscular and neurological systems work as they should. Phosphorus (P) is an essential element that is involved in a variety of physiological processes, some of the most important of which are the preservation of skeletal health, the metabolism of energy, and the activities that take place inside of cells. The Utilization of Vitamins as Markers in Various Fields of Scientific Research Consuming an adequate amount of vitamin D is necessary for the development and preservation of a strong skeletal structure as well as the efficient operation of the immune system. When levels are too high for an extended period of time, patients are at risk for developing conditions such as rickets and osteomalacia. Vitamin B12 is an essential component that helps the body produce healthy red blood cells and ensures that nerves continue to work properly. It also plays an important part in maintaining healthy nerve function. Anemia and a number of other neurological disorders can both be caused by a deficiency in a certain nutrient, which can lead to their development.

Folate, which is also known as vitamin B9, plays an essential part in the process of DNA synthesis as well as the proliferation of cells. The development of a wide variety of health problems, such as neural tube defects and anemia, can be brought on by a deficiency in particular nutrients. Vitamin C is an antioxidant that is essential for maintaining healthy immunological function and assisting in the production of collagen. Vitamin C's involvement in these processes cannot be overstated. Vitamin A is an essential component that helps keep the skin healthy, improves visual acuity, and plays an important part in keeping the immune system working properly. Vitamin E is well known for the powerful antioxidant qualities that it possesses. These characteristics aid to shield cells from the potentially damaging effects of free radicals. A significant insight into potential nutritional imbalances or deficiencies may be gained via the regular and methodical monitoring of mineral and vitamin indicators. Because of this, prompt treatments, such as dietary modifications or suitable supplements, may be carried out in the event that they are judged necessary. It is vital to participate in collaborative efforts with healthcare specialists in order to appropriately analyze these indications within the larger context of an individual's general health and their medical history.

IX. DIAGNOSTIC CHALLENGES AND LIMITATIONS

In the world of veterinary medicine, the development of biomarkers is undeniably a research topic that is seeing tremendous expansion. Emerging technologies are making successful biomarker discovery, development, and translation easier, but these tasks are still difficult for a number of reasons. These reasons include a lack of financial support, species variations, a smaller number of samples in some species, difficulty in sample collection, and a lack of method standardization or bioinformatics resources with which to analyze the output of some platforms. Despite these obstacles, successful biomarker discovery, development, and translation are becoming easier. If such issues are identified early on in the process of planning research and development, it is possible to circumvent a great deal of resistance and increase the likelihood that such initiatives will be successful. The essential requirement for close collaboration between clinicians, researchers, and funding bodies, as well as the need to set clear goals for biomarker requirements and realistic application in the clinical setting, making certain that the biomarker type, method of detection, and clinical utility are compatible, and ensuring that adequate funding, time, and sample size are available for all phases of development. If these methods are used, it will be easier for many of the promising preliminary biomarkers to reach their full potential in clinical applications. This, in turn, would reduce the amount of work that has to be done in veterinary practices, improve the wellbeing of animals, and make livestock businesses more economically viable.

The research and development of biomarkers for use in veterinary medicine has some particularly difficult obstacles. It's possible that a particular biomarker will need to be validated more than once, once for each species to which it applies. Other constraints include needs for sample handling as well as challenges in defining cut-off values due to variances across breeds. Historically, many animal biomarkers have depended on earlier experiences from human medicine to cut down on the amount of time needed for a variety of research. This has been accomplished by making use of procedures that have previously been developed and modifying them according to the needs of individual species. This application has a very narrow scope, but it might be beneficial if it is carried out with caution and adequate understanding of the species-specific variation of the biomarkers in question. Both N-terminal pro b-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT), which are cardiac biomarkers used in human medicine and have been modified to evaluate systemic inflammatory response syndrome (SIRS) in dogs, are examples of such circumstances. When it comes to human medicine, these biomarkers are well-established indicators that may be used to diagnose cardiac malfunction and evaluate prognosis. An elevated concentration of these markers has been documented in SIRS in humans, and it has been shown to be connected with myocardial hibernation. This is due to the fact that cardiac dysfunction owing to systemic inflammation has been described in human medicine and is known as myocardial hibernation. Hibernation of the heart has been observed in dogs who were given an artificially produced form of sepsis, and more recent findings reveal that plasma concentrations of cardiac biomarkers are elevated in dogs diagnosed with SIRS. Therefore, it has been hypothesized that these cardiac biomarkers may aid in the identification of cardiac dysfunction and the evaluation of prognosis in individuals who have SIRS. Additionally, it is possible that these cardiac biomarkers may be beneficial in the evaluation of dogs who have

SIRS. In point of fact, independent of the underlying conditions, researchers discovered that NT-pro BNP and cTnT levels were considerably elevated in dogs diagnosed with SIRS. In addition, the results of this study demonstrated that the concentration of cTnT was related to the survival rate of dogs diagnosed with SIRS. There is a need for research that investigates the relationship between cardiac biomarkers, echocardiographic data, and inflammatory cytokines in canine patients diagnosed with SIRS. It is abundantly clear that the history of research carried out for human applications presents a significant benefit for the development of this biomarker in animal applications and its translation to clinical veterinary practice, resulting in a reduction in the amount of time as well as financing that is necessary.

X. CONCLUSION

In colclusion, biochemical markers are essential for detecting, treating, and monitoring many animal disorders in veterinary medicine. These markers help identify diseases, forecast prognoses, and evaluate treatments in animals. Biomarkers—measurable indications of cellular, biochemical, or molecular changes—illuminate biological processes, disease processes, and therapy results. Animal health and wellbeing are crucial to society and science. Biomarkers connected to illnesses and medications must be distinguished. Risk indicators, predictive, and prognostic biomarkers indicate disease development independent of therapy. Predictive biomarkers predict therapy responses, whereas prognostic indicators predict illness outcomes regardless of treatment. medication-related biomarkers analyze medication metabolism and treatment efficacy. Blood biochemical indicators are crucial for animal health assessments. ALT, AST, ALP, and GGT elevations can suggest hepatic damage or cholestasis since the liver conducts several metabolic tasks. These indicators are not 100% specific for primary liver disease, hence a complete approach incorporating patient history, clinical symptoms, imaging, and additional testing is needed for proper diagnosis. Renal function is reliably assessed by BUN and creatinine. These elevated indicators may suggest renal dysfunction, dehydration, or decreased renal blood flow. The degree of BUN and creatinine increase indicates renal impairment. Symmetrical dimethylarginine (SDMA) increases before BUN and creatinine, allowing for early kidney disease identification and treatments. Using biochemical indicators in veterinary practice improves illness diagnosis, outcome prediction, and therapy efficacy. Understanding and using biochemical indicators will remain crucial to animal health as veterinary care advances. The cardiac troponins, creatine kinase (CK), and B-type natriuretic peptide (BNP) are necessary for animal cardiac diagnosis and evaluation. Cardiac troponins, particularly cTnI, indicate survival likelihood based on their concentrations in acute or chronic conditions. Creatine kinase (CK) is a biomarker for muscle fiber loss and may be used to diagnose necrotizing, inflammatory, and genetic muscle illnesses. Brain natriuretic peptide (BNP), released by cardiomyocytes during myocardial straining, can be used to diagnose and monitor heart conditions. NT-proBNP, a stable fraction of B-type natriuretic peptide (BNP), is used to diagnose cardiac illness. The combination of NT-proBNP data with other clinical markers greatly improves heart illness diagnosis and prognosis. These indications assist canine and feline heart health diagnosis, prediction, and monitoring. The application of biomarkers in veterinary medicine is advantageous for the identification, surveillance, and prognostication of many health ailments in animals. C-reactive protein (CRP), a biomarker often employed in veterinary medicine, serves as a diagnostic tool for identifying inflammation and systemic inflammatory response syndrome (SIRS) in canines. The temporal decline in C-reactive protein (CRP) levels has greater significance than the absolute levels, particularly in severe medical circumstances such as sepsis. Nonetheless, a fast decrease might potentially signify an unfavorable prognosis.

Although CRP offers useful insights, it should not be solely depended upon as a diagnostic tool, but rather utilized in conjunction with other diagnostic procedures. Mobile apps, commonly referred to as APPs, have the potential to assist in the monitoring of illness development and the evaluation of treatment effectiveness. However, it is important to note that these applications should be used in conjunction with clinical examinations, rather than serving as a substitute for them. Mineral and vitamin indicators are crucial factors in assessing an individual's nutritional condition and general well-being. Calcium, iron, electrolytes, magnesium, and phosphorus play pivotal roles in a multitude of physiological processes. Vitamins such as vitamin D, vitamin B12, vitamin B9 (folate), vitamin C, vitamin A, and vitamin E play a crucial role in preserving overall well-being and mitigating the risk of nutrient shortages. The act of monitoring these signs plays a crucial role in the diagnosis of deficits, providing guidance for dietary modifications, and ultimately enhancing general well-being.

Nevertheless, there are several obstacles that arise in the field of biomarker research. These challenges encompass issues such as securing adequate financial support, accounting for variances across different species, ensuring proper sample collection, and addressing the lack of standardization. In order to fully harness the potential of biomarkers in veterinary medicine, it is imperative to foster collaborative endeavors among clinicians, researchers, and funding entities. These collective efforts are essential for addressing the existing problems and effectively capitalizing on the opportunities presented by biomarkers in the field. The validation of biomarkers across diverse species and their subsequent customization to meet particular requirements is of utmost importance. Moreover, the utilization of biomarkers originally designed for human medicine can be modified for veterinary purposes by meticulous examination of species-specific discrepancies.

The utilization of biomarkers in the realm of veterinary medicine has been shown to augment the precision of diagnoses, the effectiveness of treatments, and the overall welfare of animals. This progress has significantly propelled the field forward and led to improved care for animals.

REFERENCES

[1] Kocaturk, M., Martinez, S., Eralp, O., Tvarijonaviciute, A., Ceron, J., & Yilmaz, Z. (2012). Tei index (myocardial performance index) and cardiac biomarkers in dogs with parvoviral enteritis. *Research in veterinary science*, *92*(1), 24-29.
[2] Lobetti, R., Dvir, E., & Pearson, J. (2002). Cardiac troponins in canine babesiosis. *Journal of Veterinary Internal Medicine*, *16*(1), 63-68.
[3] Hamacher, L., Dörfelt, R., Müller, M., &Wess, G. (2015). Serum cardiac troponin I concentrations in dogs with systemic inflammatory response syndrome. *Journal of veterinary internal medicine*, *29*(1), 164-170.
[4] Langhorn, R., Oyama, M. A., King, L. G., Machen, M. C., Trafny, D. J., Thawley, V., Willesen, J. L., Tarnow, I., &Kjelgaard-Hansen, M. (2013). Prognostic importance of myocardial injury in critically ill dogs with systemic inflammation. *Journal of Veterinary Internal Medicine*, *27*(4), 895-903.
[5] Langhorn, R., Thawley, V., Oyama, M. A., King, L. G., Machen, M. C., Trafny, D. J., Willesen, J. L., Tarnow, I., &Kjelgaard-Hansen, M. (2014). Prediction of long-term outcome by measurement of serum concentration of cardiac troponins in critically ill dogs with systemic inflammation. *Journal of veterinary internal medicine*, *28*(5), 1492-1497.

[6] Stein, R., Gupta, B., Agarwal, S., Golub, J., Bhutani, D., Rosman, A., &Eng, C. (2008). Prognostic implications of normal (< 0.10 ng/ml) and borderline (0.10 to 1.49 ng/ml) troponin elevation levels in critically ill patients without acute coronary syndrome. *The American journal of cardiology*, *102*(5), 509-512.
[7] Babuin, L., Vasile, V. C., Perez, J. A. R., Alegria, J. R., Chai, H. S., Afessa, B., & Jaffe, A. S. (2008). Elevated cardiac troponin is an independent risk factor for short-and long-term mortality in medical intensive care unit patients. *Critical care medicine*, *36*(3), 759-765.
[8] Kaneko, J. J., Harvey, J. W., & Bruss, M. L. (Eds.). (2008). *Clinical biochemistry of domestic animals*. Academic press.
[9] Shelton, G. D. (2010). Routine and specialized laboratory testing for the diagnosis of neuromuscular diseases in dogs and cats. *Veterinary clinical pathology*, *39*(3), 278-295.
[10] Paltrinieri, S., Cazzaniga, S., Da Cunha, N. P., & Giordano, A. (2010). Electrophoretic fractionation of creatine kinase isoenzymes and macroenzymes in clinically healthy dogs and cats and preliminary evaluation in central neurologic disease. *Veterinary Clinical Pathology*, *39*(3), 329-336.
[11] Jockers-Wretou, E., &Pfleiderer, G. (1975). Quantitation of creatine kinase isoenzymes in human tissues and sera by an immunological method. *Clinicachimica acta*, *58*(3), 223-232.
[12] Knob, M., &Seidl, I. (1980). Creatine kinase and its isoenzymes in dog sera. *ClinicaChimica Acta*, *106*(3), 287-293.
[13] Evans, J., Levesque, D., & Shelton, G. D. (2004). Canine inflammatory myopathies: a clinicopathologic review of 200 cases. *Journal of Veterinary Internal Medicine*, *18*(5), 679-691.
[14] Shelton, G. D. (2004). Rhabdomyolysis, myoglobinuria, and necrotizing myopathies. *Veterinary Clinics: Small Animal Practice*, *34*(6), 1469-1482.
[15] Shelton, G. D. (2007). From dog to man: the broad spectrum of inflammatory myopathies. *Neuromuscular disorders*, *17*(9-10), 663-670.
[16] Gonçalves, R., Penderis, J., Chang, Y. P., Zoia, A., Mosley, J., & Anderson, T. J. (2008). Clinical and neurological characteristics of aortic thromboembolism in dogs. *Journal of Small Animal Practice*, *49*(4), 178-184.
[17] Shelton, G. D., & Engvall, E. (2002). Muscular dystrophies and other inherited myopathies. *Veterinary Clinics: Small Animal Practice*, *32*(1), 103-124.
[18] Salvadori, C., Vattemi, G., Guglielmi, V., Marini, M., Tomelleri, G., &Cantile, C. (2021). Protein expression of canine and feline muscular dystrophies. *Topics in Companion Animal Medicine*, *42*, 100500.
[19] Cooley, A. J., Clemmons, R. M., & Gross, T. L. (1987). Heartworm disease manifested by encephalomyelitis and myositis in a dog. *Journal of the American Veterinary Medical Association*, *190*(4), 431-432.
[20] Buoro, I. B. J., Kanui, T. I., Atwell, R. B., Njenga, K. M., &Gathumbi, P. K. (1990). Polymyositis associated with Ehrlichiacanis infection in two dogs. *Journal of Small Animal Practice*, *31*(12), 624-627.
[21] Macintire, D. K., Vincent-Johnson, N., Dillon, A. R., Blagburn, B., Lindsay, D., Whitley, E. M., & Banfield, C. (1997). Hepatozoonosis in dogs: 22 cases (1989-1994). *Journal of the American Veterinary Medical Association*, *210*(7), 916-922.
[22] Macintire, D. K., Vincent-Johnson, N. A., Kane, C. W., Lindsay, D. S., Blagburn, B. L., & Dillon, A. R. (2001). Treatment of dogs infected with Hepatozoonamericanum: 53 cases (1989–1998). *Journal of the American Veterinary Medical Association*, *218*(1), 77-82.
[23] Podell, M. (2002). Inflammatory myopathies. *Veterinary Clinics: Small Animal Practice*, *32*(1), 147-167.
[24] Mesarcova, L., Kottferova, J., Skurkova, L., Leskova, L., &Kmecova, N. (2017). Analysis of cortisol in dog hair-a potential biomarker of chronic stress: a review. *Veterinárnímedicína*, *62*(7), 363-376.
[25] Michigan State University. (2023). Thyroid function in dogs. *Veterinary diagnostic laboratory.*https://cvm.msu.edu/vdl/laboratory-sections/endocrinology/thyroid-function-in-dogs
[26] Allen, S. E., & Holm, J. L. (2008). Lactate: physiology and clinical utility. *Journal of Veterinary Emergency and Critical Care*, *18*(2), 123-132.
[27] Moore, J. N., Owen, R. A. R., & Lumsden, J. H. (1976). Clinical evaluation of blood lactate levels in equine colic. *Equine Veterinary Journal*, *8*(2), 49-54.
[28] Jacobson, L. S., &Lobetti, R. G. (2005). Glucose, lactate, and pyruvate concentrations in dogs with babesiosis. *American journal of veterinary research*, *66*(2), 244-250.
[29] Brobst, D., Ferguson, A. B., & Carter, J. M. (1970). Evaluation of serum amylase and lipase activity in experimentally induced pancreatitis in the dog. *Journal of the American Veterinary Medical Association*, *157*(11), 1697-1702.

[30] Steiner, J. M., Newman, S., Xenoulis, P., Woosley, K., Suchodolski, J., Williams, D., & Barton, L. (2008). Sensitivity of serum markers for pancreatitis in dogs with macroscopic evidence of pancreatitis. *Veterinary therapeutics: research in applied veterinary medicine*, *9*(4), 263-273.

[31] Trivedi, S., Marks, S. L., Kass, P. H., Luff, J. A., Keller, S. M., Johnson, E. G., & Murphy, B. (2011). Sensitivity and specificity of canine pancreas-specific lipase (cPL) and other markers for pancreatitis in 70 dogs with and without histopathologic evidence of pancreatitis. *Journal of Veterinary Internal Medicine*, *25*(6), 1241-1247.

[32] Polzin, D. J., Osborne, C. A., Stevens, J. B., & Hayden, D. W. (1983). Serum amylase and lipase activities in dogs with chronic primary renal failure. *American journal of veterinary research*, *44*(3), 404-410.

[33] Jasdanwala, S., &Babyatsky, M. (2015). A critical evaluation of serum lipase and amylase as diagnostic tests for acute pancreatitis. *Integr Mol Med*, *2*(3), 189-195.

[34] McCord, K., Morley, P. S., Armstrong, J., Simpson, K., Rishniw, M., Forman, M. A., ... &Twedt, D. (2012). A Multi-Institutional Study Evaluating the Diagnostic Utility of the Spec c PL™ and SNAP® c PL™ in Clinical Acute Pancreatitis in 84 Dogs. *Journal of Veterinary Internal Medicine*, *26*(4), 888-896.

[35] Haworth, M. D., Hosgood, G., Swindells, K. L., & Mansfield, C. S. (2014). Diagnostic accuracy of the SNAP and Spec canine pancreatic lipase tests for pancreatitis in dogs presenting with clinical signs of acute abdominal disease. *Journal of Veterinary Emergency and Critical Care*, *24*(2), 135-143.

[36] Cridge, H., MacLeod, A. G., Pachtinger, G. E., Mackin, A. J., Sullivant, A. M., Thomason, J. M., Archer T.M., Lunsford, K.V., Rosenthal, K. & Wills, R. W. (2018). Evaluation of SNAP cPL, Spec cPL, VetScancPL rapid test, and precision PSL assays for the diagnosis of clinical pancreatitis in dogs. *Journal of veterinary internal medicine*, *32*(2), 658-664.

[37] Cridge, H., Twedt, D. C., Marolf, A. J., Sharkey, L. C., & Steiner, J. M. (2021). Advances in the diagnosis of acute pancreatitis in dogs. *Journal of Veterinary Internal Medicine*, *35*(6), 2572-2587.

[38] Mori, N., Lee, P., Kondo, K., Kido, T., Saito, T., & Arai, T. (2011). Potential use of cholesterol lipoprotein profile to confirm obesity status in dogs. *Veterinary research communications*, *35*, 223-235.

